Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Colorectal Neoplasms

  Free Subscription


21.05.2018

2 Ann Surg Oncol
2 Anticancer Res
1 BMC Cancer
2 Br J Cancer
1 Curr Treat Options Oncol
1 Dis Colon Rectum
1 Eur J Gastroenterol Hepatol
1 Eur J Surg Oncol
1 Hum Pathol
1 Int J Cancer
1 Int J Colorectal Dis
1 Int J Oncol
1 J Pathol
1 J Surg Oncol
2 Lancet
1 Oncogene


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. NARAYANAN S, Kawaguchi T, Yan L, Peng X, et al
    Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
    Ann Surg Oncol. 2018 May 16. pii: 10.1245/s10434-018-6506.
    PubMed     Text format     Abstract available

  2. VAN DEN BROEK J, Geenen R, Heijnen L, Kobus C, et al
    Adrenal Incidentalomas During Diagnostic Work-up of Colorectal Cancer Patients: What is the Risk of Metastases?
    Ann Surg Oncol. 2018 May 14. pii: 10.1245/s10434-018-6501.
    PubMed     Text format     Abstract available


    Anticancer Res

  3. CUSHMAN TR, Venigalla S, Brooks ED, Lin C, et al
    Utilization of Neoadjuvant Intensity-modulated Radiation Therapy for Rectal Cancer in the United States.
    Anticancer Res. 2018;38:2923-2927.
    PubMed     Text format     Abstract available

  4. JOO JW, Kim HS, Do SI, Sung JY, et al
    Expression of Zinc Finger and BTB Domain-containing 7A in Colorectal Carcinoma.
    Anticancer Res. 2018;38:2787-2792.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. YANG L, Xiong Z, Xie Q, He W, et al
    Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer.
    BMC Cancer. 2018;18:558.
    PubMed     Text format     Abstract available


    Br J Cancer

  6. ZUNDER SM, van Pelt GW, Gelderblom HJ, Mancao C, et al
    Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0083.
    PubMed     Text format     Abstract available

  7. MA R, Xu L, Qu X, Che X, et al
    AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0086.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  8. DAS S, Ciombor KK, Haraldsdottir S, Goldberg RM, et al
    Promising New Agents for Colorectal Cancer.
    Curr Treat Options Oncol. 2018;19:29.
    PubMed     Text format     Abstract available


    Dis Colon Rectum

  9. KANTERS AE, Morris AM, Abrahamse PH, Mody L, et al
    The Effect of Peer Support on Colorectal Cancer Patients' Adherence to Guideline-Concordant Multidisciplinary Care.
    Dis Colon Rectum. 2018 May 15. doi: 10.1097/DCR.0000000000001067.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  10. CATALANO C, da Silva Filho MI, Jiraskova K, Vymetalkova V, et al
    Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001154.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  11. MINNELLA EM, Carli F
    Prehabilitation and functional recovery for colorectal cancer patients.
    Eur J Surg Oncol. 2018 Apr 30. pii: S0748-7983(18)31022.
    PubMed     Text format     Abstract available


    Hum Pathol

  12. PYO JS, Park MJ, Kim CN
    TPL2 expression is correlated with distant metastasis and poor prognosis in colorectal cancer.
    Hum Pathol. 2018 May 12. pii: S0046-8177(18)30160.
    PubMed     Text format     Abstract available


    Int J Cancer

  13. TAYLOR ES, McCall JL, Shen S, Girardin A, et al
    Prognostic roles for IL-2-producing and CD69(+) T cell subsets in colorectal cancer patients.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31598.
    PubMed     Text format     Abstract available


    Int J Colorectal Dis

  14. LIU Q, Ma Y, Luo D, Cai S, et al
    Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer.
    Int J Colorectal Dis. 2018 May 16. pii: 10.1007/s00384-018-3071.
    PubMed     Text format     Abstract available


    Int J Oncol

  15. ZHANG Y, Feng Y, Ji D, Wang Q, et al
    TRIM27 functions as an oncogene by activating epithelial-mesenchymal transition and p-AKT in colorectal cancer.
    Int J Oncol. 2018 May 16. doi: 10.3892/ijo.2018.4408.
    PubMed     Text format     Abstract available


    J Pathol

  16. ETO T, Miyake K, Nosho K, Ohmuraya M, et al
    Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression.
    J Pathol. 2018 May 13. doi: 10.1002/path.5098.
    PubMed     Text format     Abstract available


    J Surg Oncol

  17. CHOE EK, Yi JW, Chai YJ, Park KJ, et al
    Upregulation of the adipokine genes ADIPOR1 and SPP1 is related to poor survival outcomes in colorectal cancer.
    J Surg Oncol. 2018 May 14. doi: 10.1002/jso.25078.
    PubMed     Text format     Abstract available


    Lancet

  18. PAGES F, Mlecnik B, Marliot F, Bindea G, et al
    International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
    Lancet. 2018 May 10. pii: S0140-6736(18)30789.
    PubMed     Text format     Abstract available

  19. OGINO S, Giannakis M
    Immunoscore for (colorectal) cancer precision medicine.
    Lancet. 2018 May 10. pii: S0140-6736(18)30953.
    PubMed     Text format    


    Oncogene

  20. KNICKELBEIN K, Tong J, Chen D, Wang YJ, et al
    Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0289.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: